Neurologic manifestations associated with parvovirus B19 infection

Miltiadis Douvoyiannis, Nathan Litman, David L. Goldman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Eighty-one cases of neurologic disease, including encephalitis, meningitis, stroke, and peripheral neuropathy, that were associated with parvovirus B19 infection were reviewed. Most patients were children, and two-thirds had central nervous system manifestations. One-third had altered immunity. Viral symptoms (odds ratio [OR], 5.7; P = .002), rash (OR, 11.5; P < .001), and peripheral nervous system involvement (OR, 12.1; P = .004) were more frequent in immunocompetent patients. Brain magnetic resonance imaging abnormalities were more frequent in patients with altered immunity (OR, 10; P = .04). In central nervous system disease, parvovirus B19 DNA was commonly detected in cerebrospinal fluid (81% of samples) and serum (85%), whereas specific antibodies were found in 33% of cerebrospinal fluid samples. Neurologic sequelae occurred in 22% of 77 patients with a known outcome, and some improvement occurred in 16%. No differences in the prevalence of sequealae were noted between immunocompetent patients (21% of whom experienced sequealae) and patients with altered immunity (25%) or between patients with central nervous system manifestations who received intravenous immunoglobulin with or without steroids and those patients with central nervous system manifestations who did not. Five patients died.

Original languageEnglish (US)
Pages (from-to)1713-1723
Number of pages11
JournalClinical Infectious Diseases
Volume48
Issue number12
DOIs
StatePublished - Jun 15 2009

Fingerprint

Parvoviridae Infections
Neurologic Manifestations
Odds Ratio
Immunity
Central Nervous System
Cerebrospinal Fluid
Parvovirus
Intravenous Immunoglobulins
Central Nervous System Diseases
Peripheral Nervous System
Peripheral Nervous System Diseases
Encephalitis
Exanthema
Nervous System Diseases
Meningitis
Nervous System
Stroke
Steroids
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Neurologic manifestations associated with parvovirus B19 infection. / Douvoyiannis, Miltiadis; Litman, Nathan; Goldman, David L.

In: Clinical Infectious Diseases, Vol. 48, No. 12, 15.06.2009, p. 1713-1723.

Research output: Contribution to journalArticle

Douvoyiannis, Miltiadis ; Litman, Nathan ; Goldman, David L. / Neurologic manifestations associated with parvovirus B19 infection. In: Clinical Infectious Diseases. 2009 ; Vol. 48, No. 12. pp. 1713-1723.
@article{81de30fa72b84bd693c267e48be38090,
title = "Neurologic manifestations associated with parvovirus B19 infection",
abstract = "Eighty-one cases of neurologic disease, including encephalitis, meningitis, stroke, and peripheral neuropathy, that were associated with parvovirus B19 infection were reviewed. Most patients were children, and two-thirds had central nervous system manifestations. One-third had altered immunity. Viral symptoms (odds ratio [OR], 5.7; P = .002), rash (OR, 11.5; P < .001), and peripheral nervous system involvement (OR, 12.1; P = .004) were more frequent in immunocompetent patients. Brain magnetic resonance imaging abnormalities were more frequent in patients with altered immunity (OR, 10; P = .04). In central nervous system disease, parvovirus B19 DNA was commonly detected in cerebrospinal fluid (81{\%} of samples) and serum (85{\%}), whereas specific antibodies were found in 33{\%} of cerebrospinal fluid samples. Neurologic sequelae occurred in 22{\%} of 77 patients with a known outcome, and some improvement occurred in 16{\%}. No differences in the prevalence of sequealae were noted between immunocompetent patients (21{\%} of whom experienced sequealae) and patients with altered immunity (25{\%}) or between patients with central nervous system manifestations who received intravenous immunoglobulin with or without steroids and those patients with central nervous system manifestations who did not. Five patients died.",
author = "Miltiadis Douvoyiannis and Nathan Litman and Goldman, {David L.}",
year = "2009",
month = "6",
day = "15",
doi = "10.1086/599042",
language = "English (US)",
volume = "48",
pages = "1713--1723",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Neurologic manifestations associated with parvovirus B19 infection

AU - Douvoyiannis, Miltiadis

AU - Litman, Nathan

AU - Goldman, David L.

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Eighty-one cases of neurologic disease, including encephalitis, meningitis, stroke, and peripheral neuropathy, that were associated with parvovirus B19 infection were reviewed. Most patients were children, and two-thirds had central nervous system manifestations. One-third had altered immunity. Viral symptoms (odds ratio [OR], 5.7; P = .002), rash (OR, 11.5; P < .001), and peripheral nervous system involvement (OR, 12.1; P = .004) were more frequent in immunocompetent patients. Brain magnetic resonance imaging abnormalities were more frequent in patients with altered immunity (OR, 10; P = .04). In central nervous system disease, parvovirus B19 DNA was commonly detected in cerebrospinal fluid (81% of samples) and serum (85%), whereas specific antibodies were found in 33% of cerebrospinal fluid samples. Neurologic sequelae occurred in 22% of 77 patients with a known outcome, and some improvement occurred in 16%. No differences in the prevalence of sequealae were noted between immunocompetent patients (21% of whom experienced sequealae) and patients with altered immunity (25%) or between patients with central nervous system manifestations who received intravenous immunoglobulin with or without steroids and those patients with central nervous system manifestations who did not. Five patients died.

AB - Eighty-one cases of neurologic disease, including encephalitis, meningitis, stroke, and peripheral neuropathy, that were associated with parvovirus B19 infection were reviewed. Most patients were children, and two-thirds had central nervous system manifestations. One-third had altered immunity. Viral symptoms (odds ratio [OR], 5.7; P = .002), rash (OR, 11.5; P < .001), and peripheral nervous system involvement (OR, 12.1; P = .004) were more frequent in immunocompetent patients. Brain magnetic resonance imaging abnormalities were more frequent in patients with altered immunity (OR, 10; P = .04). In central nervous system disease, parvovirus B19 DNA was commonly detected in cerebrospinal fluid (81% of samples) and serum (85%), whereas specific antibodies were found in 33% of cerebrospinal fluid samples. Neurologic sequelae occurred in 22% of 77 patients with a known outcome, and some improvement occurred in 16%. No differences in the prevalence of sequealae were noted between immunocompetent patients (21% of whom experienced sequealae) and patients with altered immunity (25%) or between patients with central nervous system manifestations who received intravenous immunoglobulin with or without steroids and those patients with central nervous system manifestations who did not. Five patients died.

UR - http://www.scopus.com/inward/record.url?scp=66949144407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949144407&partnerID=8YFLogxK

U2 - 10.1086/599042

DO - 10.1086/599042

M3 - Article

C2 - 19441978

AN - SCOPUS:66949144407

VL - 48

SP - 1713

EP - 1723

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -